Romain Sechaud1, Surendra Machineni2, Hanns-Christian Tillmann3, Hisanori Hara4, Xuemei Tan5, Rong Zhao6, Shuang Ren6, Jie Hou7. 1. Novartis Institutes for Biomedical Research, WSJ-386-12.48.13, Novartis Campus, 4002, Basel, Switzerland. romain.sechaud@novartis.com. 2. Novartis Healthcare Pvt. Ltd, Hyderabad, India. 3. Novartis Institutes for Biomedical Research, WSJ-386-12.48.13, Novartis Campus, 4002, Basel, Switzerland. 4. Novartis Institutes for Biomedical Research, WSJ-153.3.02.2, Novartis Campus, 4002, Basel, Switzerland. 5. Novartis Institutes for Biomedical Research, Beijing, People's Republic of China. 6. Novartis Institutes for Biomedical Research, Shanghai, People's Republic of China. 7. TICH, TEDA, Tianjin, People's Republic of China.
Abstract
BACKGROUND AND OBJECTIVES: Glycopyrronium is a once-daily long-acting muscarinic antagonist for the maintenance treatment of patients with chronic obstructive pulmonary disease. This study assessed the pharmacokinetics of inhaled glycopyrronium 50 µg once-daily for 14 days in healthy Chinese subjects. METHODS: In this open-label study, 12 Chinese healthy subjects (six males and six females; mean age 23.1 years [range 18-26 years]) were enrolled and completed the study. Glycopyrronium in plasma was determined using validated liquid chromatography-mass spectrometry method with a lower limit of quantification of 1.5 pg/mL. Plasma pharmacokinetic parameters were determined on Day 1 after first dose and on Day 14 (steady state) after last dose using non-compartmental analysis. Trough pharmacokinetic samples (Days 5, 7, 10 and 12) were collected. Safety was also assessed. RESULTS: Glycopyrronium was rapidly absorbed into the systemic circulation after inhalation and its plasma concentrations decreased rapidly thereafter. Median time to reach maximum concentration (T max) was reached within 5 min after inhalation on both Days 1 and 14. Accumulation in the systemic exposure to glycopyrronium was observed from the time of first dose administration on Day 1 up to Day 14 and the observed accumulation ratio (R acc) values of area under the plasma drug concentration-time curve [AUC] from time 0 to 24 h post-dose (AUC0-24h) and maximum plasma drug concentration (C max) (Day 14/Day 1) were 2.77 and 1.59, respectively. The elimination half-life (T 1/2) was not reported. Mean effective half-life (T 1/2,acc) was 37.7 h. Pharmacokinetic steady state was reached after 5 days of daily dosing. One subject experienced dry mouth; otherwise glycopyrronium was well tolerated. CONCLUSIONS: Comparison of systemic exposure to glycopyrronium in Chinese versus the non-Chinese population did not indicate clinically relevant ethnic differences. Multiple inhaled doses of glycopyrronium were safe and well tolerated.
BACKGROUND AND OBJECTIVES:Glycopyrronium is a once-daily long-acting muscarinic antagonist for the maintenance treatment of patients with chronic obstructive pulmonary disease. This study assessed the pharmacokinetics of inhaled glycopyrronium 50 µg once-daily for 14 days in healthy Chinese subjects. METHODS: In this open-label study, 12 Chinese healthy subjects (six males and six females; mean age 23.1 years [range 18-26 years]) were enrolled and completed the study. Glycopyrronium in plasma was determined using validated liquid chromatography-mass spectrometry method with a lower limit of quantification of 1.5 pg/mL. Plasma pharmacokinetic parameters were determined on Day 1 after first dose and on Day 14 (steady state) after last dose using non-compartmental analysis. Trough pharmacokinetic samples (Days 5, 7, 10 and 12) were collected. Safety was also assessed. RESULTS:Glycopyrronium was rapidly absorbed into the systemic circulation after inhalation and its plasma concentrations decreased rapidly thereafter. Median time to reach maximum concentration (T max) was reached within 5 min after inhalation on both Days 1 and 14. Accumulation in the systemic exposure to glycopyrronium was observed from the time of first dose administration on Day 1 up to Day 14 and the observed accumulation ratio (R acc) values of area under the plasma drug concentration-time curve [AUC] from time 0 to 24 h post-dose (AUC0-24h) and maximum plasma drug concentration (C max) (Day 14/Day 1) were 2.77 and 1.59, respectively. The elimination half-life (T 1/2) was not reported. Mean effective half-life (T 1/2,acc) was 37.7 h. Pharmacokinetic steady state was reached after 5 days of daily dosing. One subject experienced dry mouth; otherwise glycopyrronium was well tolerated. CONCLUSIONS: Comparison of systemic exposure to glycopyrronium in Chinese versus the non-Chinese population did not indicate clinically relevant ethnic differences. Multiple inhaled doses of glycopyrronium were safe and well tolerated.
Authors: Romain Sechaud; Didier Renard; Lixin Zhang-Auberson; Stephan de la Motte; Anton Drollmann; Guenther Kaiser Journal: Int J Clin Pharmacol Ther Date: 2012-02 Impact factor: 1.366
Authors: Anthony D'Urzo; Gary T Ferguson; Jan A van Noord; Kazuto Hirata; Carmen Martin; Rachael Horton; Yimeng Lu; Donald Banerji; Tim Overend Journal: Respir Res Date: 2011-12-07
Authors: Edward Kerwin; Jacques Hébert; Nicola Gallagher; Carmen Martin; Tim Overend; Vijay K T Alagappan; Yimeng Lu; Donald Banerji Journal: Eur Respir J Date: 2012-07-26 Impact factor: 16.671
Authors: Harm Maarsingh; Anouk Oldenburger; Bing Han; Annet B Zuidhof; Carolina R S Elzinga; Wim Timens; Herman Meurs; Ramadan B Sopi; Martina Schmidt Journal: Cells Date: 2021-05-18 Impact factor: 6.600